Karyopharm Retained Earnings Total Equity from 2010 to 2024

KPTI Stock  USD 1.14  0.01  0.87%   
Karyopharm Therapeutics' Retained Earnings Total Equity is decreasing with slightly volatile movements from year to year. Retained Earnings Total Equity is estimated to finish at about -1.1 B this year. Retained Earnings Total Equity is the portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt. View All Fundamentals
 
Retained Earnings Total Equity  
First Reported
2013-09-30
Previous Quarter
-1.3 B
Current Value
-1.4 B
Quarterly Volatility
433.1 M
 
Yuan Drop
 
Covid
Check Karyopharm Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Karyopharm main balance sheet or income statement drivers, such as Depreciation And Amortization of 503.5 K, Interest Expense of 25 M or Selling General Administrative of 67.5 M, as well as many exotic indicators such as Price To Sales Ratio of 0.64, Dividend Yield of 0.0 or Days Sales Outstanding of 52.74. Karyopharm financial statements analysis is a perfect complement when working with Karyopharm Therapeutics Valuation or Volatility modules.
  
This module can also supplement Karyopharm Therapeutics' financial leverage analysis and stock options assessment as well as various Karyopharm Therapeutics Technical models . Check out the analysis of Karyopharm Therapeutics Correlation against competitors.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

Latest Karyopharm Therapeutics' Retained Earnings Total Equity Growth Pattern

Below is the plot of the Retained Earnings Total Equity of Karyopharm Therapeutics over the last few years. It is the portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt. Karyopharm Therapeutics' Retained Earnings Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Karyopharm Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Retained Earnings Total Equity10 Years Trend
Slightly volatile
   Retained Earnings Total Equity   
       Timeline  

Karyopharm Retained Earnings Total Equity Regression Statistics

Arithmetic Mean(600,299,396)
Coefficient Of Variation(82.26)
Mean Deviation439,440,156
Median(495,341,000)
Standard Deviation493,824,168
Sample Variance243862.3T
Range1.3B
R-Value(0.96)
Mean Square Error20393.4T
R-Squared0.92
Slope(106,048,484)
Total Sum of Squares3414072.3T

Karyopharm Retained Earnings Total Equity History

2024-1.1 B
2023-1.2 B
2022-1.3 B
2021-1.2 B
2020-1.1 B
2019-873.3 M
2018-673.7 M

About Karyopharm Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Karyopharm Therapeutics income statement, its balance sheet, and the statement of cash flows. Karyopharm Therapeutics investors use historical funamental indicators, such as Karyopharm Therapeutics's Retained Earnings Total Equity, to determine how well the company is positioned to perform in the future. Although Karyopharm Therapeutics investors may use each financial statement separately, they are all related. The changes in Karyopharm Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Karyopharm Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Karyopharm Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Karyopharm Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Retained Earnings Total Equity-1.2 B-1.1 B

Currently Active Assets on Macroaxis

When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:
Check out the analysis of Karyopharm Therapeutics Correlation against competitors.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Karyopharm Stock analysis

When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Commodity Directory
Find actively traded commodities issued by global exchanges
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Equity Valuation
Check real value of public entities based on technical and fundamental data
Is Karyopharm Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.27)
Revenue Per Share
1.224
Quarterly Revenue Growth
(0.14)
Return On Assets
(0.31)
Return On Equity
(8.91)
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.